157 related articles for article (PubMed ID: 11446524)
1. A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
Feagan BG
Pharmacotherapy; 2001 Jul; 21(7 Pt 2):89S-94S. PubMed ID: 11446524
[TBL] [Abstract][Full Text] [Related]
2. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin.
Palmer CS; Zhan C; Elixhauser A; Halpern MT; Rance L; Feagan BG; Marrie TJ
Clin Ther; 2000 Feb; 22(2):250-64. PubMed ID: 10743984
[TBL] [Abstract][Full Text] [Related]
3. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
Marrie TJ; Lau CY; Wheeler SL; Wong CJ; Vandervoort MK; Feagan BG
JAMA; 2000 Feb; 283(6):749-55. PubMed ID: 10683053
[TBL] [Abstract][Full Text] [Related]
4. Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience.
Milkovich G
Pharmacotherapy; 2001 Jul; 21(7 Pt 2):83S-88S. PubMed ID: 11446523
[TBL] [Abstract][Full Text] [Related]
5. Approaches to drug therapy, formulary, and pathway management in a large community hospital.
Halley HJ
Am J Health Syst Pharm; 2000 Nov; 57 Suppl 3():S17-21. PubMed ID: 11098316
[TBL] [Abstract][Full Text] [Related]
6. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
7. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.
Clark LC; Davis CW
Am J Health Syst Pharm; 2000 Nov; 57 Suppl 3():S10-3. PubMed ID: 11098314
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
Friedman H; Song X; Crespi S; Navaratnam P
Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
[TBL] [Abstract][Full Text] [Related]
9. Outpatient care compared with hospitalization for community-acquired pneumonia: a randomized trial in low-risk patients.
Carratalà J; Fernández-Sabé N; Ortega L; Castellsagué X; Rosón B; Dorca J; Fernández-Agüera A; Verdaguer R; Martínez J; Manresa F; Gudiol F
Ann Intern Med; 2005 Feb; 142(3):165-72. PubMed ID: 15684204
[TBL] [Abstract][Full Text] [Related]
10. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
Samsa GP; Matchar DB; Harnett J; Wilson J
Chest; 2005 Nov; 128(5):3246-54. PubMed ID: 16304269
[TBL] [Abstract][Full Text] [Related]
11. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Signorovitch JE; Sheng Duh M; Sengupta A; Gu A; Grant R; Raut M; Mody SH; Schein J; Fisher AC; Ng D
Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
[TBL] [Abstract][Full Text] [Related]
12. Managing antiinfective therapy of community-acquired pneumonia in the hospital setting: focus on switch therapy.
Ramirez JA
Pharmacotherapy; 2001 Jul; 21(7 Pt 2):79S-82S. PubMed ID: 11446522
[TBL] [Abstract][Full Text] [Related]
13. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
Lloyd A; Holman A; Evers T
Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumonia.
Shorr AF; Zadeikis N; Xiang JX; Tennenberg AM; Wes Ely E
Clin Ther; 2005 Aug; 27(8):1251-9. PubMed ID: 16199249
[TBL] [Abstract][Full Text] [Related]
15. Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia.
Erard V; Lamy O; Bochud PY; Bille J; Cometta A; Calandra T
Eur J Clin Microbiol Infect Dis; 2004 Feb; 23(2):82-8. PubMed ID: 14727149
[TBL] [Abstract][Full Text] [Related]
16. [Update on the role of levofloxacin in the management of acute community-acquired pneumonia].
Bru JP
Presse Med; 2002 Jun; 31(21 Pt 2):S19-22. PubMed ID: 12148386
[TBL] [Abstract][Full Text] [Related]
17. [Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization].
Kalbermatter V; Bagilet D; Diab M; Javkin E
Med Clin (Barc); 2000 Nov; 115(15):561-3. PubMed ID: 11141388
[TBL] [Abstract][Full Text] [Related]
18. Can an antimicrobial stewardship program reduce length of stay of immune-competent adult patients admitted to hospital with diagnosis of community-acquired pneumonia? Study protocol for pragmatic controlled non-randomized clinical study.
DiDiodato G; McArthur L; Beyene J; Smieja M; Thabane L
Trials; 2015 Aug; 16():355. PubMed ID: 26272324
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of an algorithm for switching from IV to PO therapy in clinical practice in patients with community-acquired pneumonia.
van der Eerden MM; de Graaff CS; Vlaspolder F; Bronsveld W; Jansen HM; Boersma WG
Clin Ther; 2004 Feb; 26(2):294-303. PubMed ID: 15038952
[TBL] [Abstract][Full Text] [Related]
20. Experience with levofloxacin in a critical pathway for the treatment of community-acquired pneumonia.
Marrie TJ
Chemotherapy; 2004; 50 Suppl 1():11-5. PubMed ID: 15319549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
